AB928

Research use only, not for human use.

AB928 is a dual antagonist of the A2aR and A2bR adenosine receptors leads to greater immune activation and reduced tumor growth when combined with chemotherapy.

AB928 is a dual antagonist of the A2aR and A2bR adenosine receptors leads to greater immune activation and reduced tumor growth when combined with chemotherapy(In Vitro):In human in vitro cell cultures, moDC differentiated in the presence of adenosine showed a decreased ability to stimulate IFN-γ secretion from allogenic CD4+ T-cells in a MLR. This suppression is significantly reversed by addition of Etrumadenant. Multiplexed gene expression profiling using NanoString identified a cassette of 39 genes that are regulated by adenosine during moDC differentiation. Etrumadenant shows rescue of these gene expression changes.(In Vivo):Concurrent treatment with Etrumadenant and chemotherapy results in significantly reduced tumor volume in vivo using AT3-OVA tumors; Similar results are observed for the combination of Etrumadenant and NSC 266046. AB928 is also capable of suppressing growth of B16-F10 tumors both as a single agent or in combination with α-PD-1 therapy. Etrumadenant increases the antitumor immune response leading to suppressed tumor growth and increased immune cell infiltration in mouse syngeneic tumors.

In human in vitro cell cultures, moDC differentiated in the presence of adenosine showed a decreased ability to stimulate IFN-γ secretion from allogenic CD4+ T-cells in a MLR. This suppression is significantly reversed by addition of Etrumadenant. Multiplexed gene expression profiling using NanoString identified a cassette of 39 genes that are regulated by adenosine during moDC differentiation. Etrumadenant shows rescue of these gene expression changes.

Concurrent treatment with Etrumadenant and chemotherapy results in significantly reduced tumor volume in vivo using AT3-OVA tumors; Similar results are observed for the combination of Etrumadenant and NSC 266046. AB928 is also capable of suppressing growth of B16-F10 tumors both as a single agent or in combination with α-PD-1 therapy. Etrumadenant increases the antitumor immune response leading to suppressed tumor growth and increased immune cell infiltration in mouse syngeneic tumors.

AB928 | AB-928 | AB 928

Apoptosis

Adenosine Receptor

A2aR/A2bR

——

——

2239273-34-6

426.47

C??H??N?O

>98% (HPLC)

DMSO : 250 mg/mL (586.21 mM; Need ultrasonic)

N#CC1=CC=CC(C2=NC(N)=NC(C3=CN(CC4=NC(C(C)(O)C)=CC=C4)N=N3)=C2)=C1C

3-[2-Amino-6-[1-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazol-4-yl]pyrimidin-4-yl]-2-methylbenzonitrile

(-20℃)

With Ice Pack

≥ 2 years